The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prognostic value of KRAS in terms of efficacy and safety of bevacizumab as neoadjuvant or conversion treatment in patients with colorectal liver metastasis.
Pilar Garcia Alfonso
No relevant relationships to disclose
Andrés Jesús Muñoz Martin
No relevant relationships to disclose
Sonsoles Alvarez
No relevant relationships to disclose
M. Carmen Riesco
No relevant relationships to disclose
Montse Blanco Codeisido
No relevant relationships to disclose
Ana Belen Ruperez Blanco
No relevant relationships to disclose
Sara Custodio Cabello
No relevant relationships to disclose
Gonzalo Tapia
No relevant relationships to disclose
Rebeca Mondejar Solís
No relevant relationships to disclose
Miguel Martin
No relevant relationships to disclose